Eli Lilly and Company (NYSE:LLY) had its price target lifted by Morgan Stanley from $86.00 to $90.00 in a research report released on Tuesday. The brokerage currently has an equal weight rating on the stock.
LLY has been the subject of a number of other research reports. Jefferies Group LLC reaffirmed a buy rating and issued a $89.00 target price on shares of Eli Lilly and in a research report on Monday, September 11th. BMO Capital Markets reaffirmed an underperform rating and issued a $71.00 target price (down previously from $73.00) on shares of Eli Lilly and in a research report on Wednesday, September 6th. Piper Jaffray Companies reaffirmed an overweight rating and issued a $105.00 target price (up previously from $103.00) on shares of Eli Lilly and in a research report on Friday, September 8th. Credit Suisse Group downgraded shares of Eli Lilly and from an outperform rating to a neutral rating and raised their target price for the company from $84.23 to $88.00 in a research report on Tuesday, October 10th. Finally, Berenberg Bank reaffirmed a buy rating and issued a $98.00 target price on shares of Eli Lilly and in a research report on Thursday, October 26th. Three research analysts have rated the stock with a sell rating, eight have assigned a hold rating and ten have assigned a buy rating to the company’s stock. Eli Lilly and presently has a consensus rating of Hold and an average price target of $89.97.
Shares of Eli Lilly and (NYSE LLY) opened at $83.51 on Tuesday. The company has a current ratio of 1.38, a quick ratio of 1.03 and a debt-to-equity ratio of 0.66. Eli Lilly and has a 12-month low of $64.18 and a 12-month high of $89.09. The stock has a market cap of $91,589.09, a price-to-earnings ratio of 20.34, a PEG ratio of 1.84 and a beta of 0.34.
Eli Lilly and (NYSE:LLY) last issued its quarterly earnings data on Tuesday, October 24th. The company reported $1.05 earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of $1.03 by $0.02. Eli Lilly and had a net margin of 9.90% and a return on equity of 30.27%. The company had revenue of $5.66 billion during the quarter, compared to the consensus estimate of $5.52 billion. During the same quarter in the prior year, the firm earned $0.88 earnings per share. The firm’s revenue was up 9.0% compared to the same quarter last year. research analysts expect that Eli Lilly and will post 4.21 EPS for the current fiscal year.
ILLEGAL ACTIVITY NOTICE: This report was posted by TrueBlueTribune and is the property of of TrueBlueTribune. If you are reading this report on another publication, it was copied illegally and republished in violation of US and international trademark and copyright law. The original version of this report can be viewed at https://www.truebluetribune.com/2017/11/22/eli-lilly-and-company-lly-price-target-raised-to-90-00-at-morgan-stanley.html.
The firm also recently disclosed a quarterly dividend, which will be paid on Friday, December 8th. Shareholders of record on Wednesday, November 15th will be paid a $0.52 dividend. This represents a $2.08 annualized dividend and a yield of 2.49%. The ex-dividend date is Tuesday, November 14th. Eli Lilly and’s dividend payout ratio (DPR) is 98.58%.
In other Eli Lilly and news, major shareholder Lilly Endowment Inc sold 190,000 shares of Eli Lilly and stock in a transaction dated Friday, September 15th. The shares were sold at an average price of $82.53, for a total value of $15,680,700.00. Following the completion of the sale, the insider now owns 123,682,287 shares in the company, valued at approximately $10,207,499,146.11. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Also, SVP Alfonso G. Zulueta sold 2,003 shares of the firm’s stock in a transaction dated Friday, November 10th. The shares were sold at an average price of $83.67, for a total transaction of $167,591.01. Following the completion of the transaction, the senior vice president now directly owns 43,580 shares in the company, valued at $3,646,338.60. The disclosure for this sale can be found here. Insiders sold a total of 772,003 shares of company stock valued at $64,837,441 in the last quarter. Corporate insiders own 0.20% of the company’s stock.
A number of hedge funds have recently added to or reduced their stakes in LLY. BlackRock Inc. increased its holdings in Eli Lilly and by 2,628.5% in the 1st quarter. BlackRock Inc. now owns 62,260,488 shares of the company’s stock valued at $5,236,731,000 after buying an additional 59,978,664 shares during the period. Janus Henderson Group PLC increased its holdings in Eli Lilly and by 7,093.5% in the 2nd quarter. Janus Henderson Group PLC now owns 9,353,275 shares of the company’s stock valued at $769,774,000 after buying an additional 9,223,251 shares during the period. Dodge & Cox increased its holdings in Eli Lilly and by 22,094.9% in the 2nd quarter. Dodge & Cox now owns 5,991,952 shares of the company’s stock valued at $493,138,000 after buying an additional 5,964,955 shares during the period. Renaissance Technologies LLC increased its holdings in Eli Lilly and by 91.1% in the 2nd quarter. Renaissance Technologies LLC now owns 5,694,905 shares of the company’s stock valued at $468,691,000 after buying an additional 2,714,505 shares during the period. Finally, Vanguard Group Inc. increased its holdings in Eli Lilly and by 3.3% in the 1st quarter. Vanguard Group Inc. now owns 68,597,006 shares of the company’s stock valued at $5,769,694,000 after buying an additional 2,181,701 shares during the period. 76.61% of the stock is currently owned by hedge funds and other institutional investors.
Eli Lilly and Company Profile
Eli Lilly and Company is engaged in drug manufacturing business. The Company discovers, develops, manufactures and markets products in two segments: human pharmaceutical products and animal health products. The Company’s human pharmaceutical business segment sells medicines, which are discovered or developed by its scientists.
Receive News & Ratings for Eli Lilly and Company Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eli Lilly and Company and related companies with MarketBeat.com's FREE daily email newsletter.